Part D Sponsors Limited To Two Drug Plans Per Region Due To Donut Hole Phase Out, Rule States
This article was originally published in The Pink Sheet Daily
CMS cites the closing of the coverage gap under the Affordable Care Act as rationale for permitting drug plan sponsors to offer no more than one basic and one enhanced stand-alone prescription drug plan in each region, starting in 2016.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.